Survodutide
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
Boehringer Ingelheim · Phase 3 · Completed · Enrollment 5530
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| survodutide 3.6 mg | Obesity or overweight | 3.6 mg | n/r | n/r | n/r |
| survodutide 6.0 mg | Obesity or overweight | 6.0 mg | n/r | n/r | n/r |
| Placebo | Obesity or overweight | n/r | n/r | n/r | n/r |